SFCM
EWTX icon

Seven Fleet Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Seven Fleet Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$369K Buy
11,701
+9,701
+485% +$280K 0.12% 91
2025
Q4 		$49.6K Buy
+2,000
New +$40.1K 0.03% 79

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Seven Fleet Capital Management's EWTX Position: Q1 2026 in Review

Seven Fleet Capital Management increased its Edgewise Therapeutics (EWTX) stake by 485% in Q1 2026, buying an estimated $280K and bringing the position to 11,701 shares worth $369K. The position accounts for 0.12% of the portfolio, ranked #91.

Seven Fleet Capital Management first reported a position in EWTX in Q4 2025 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Seven Fleet Capital Management held 11,701 shares of Edgewise Therapeutics worth $369K as of Q1 2026.
  • Seven Fleet Capital Management bought 9,701 Edgewise Therapeutics shares in Q1 2026, an estimated $280K.
  • Edgewise Therapeutics made up 0.12% of Seven Fleet Capital Management's portfolio in Q1 2026, its #91 holding.
  • Seven Fleet Capital Management first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.